Home Protein Tyrosine Kinase c-Met inhibitor Ningetinib

research use only

Ningetinib c-Met inhibitor

Cat.No.S6870

Ningetinib (CT-053, DE-120, CT053PTSA) is a potent, orally bioavailable inhibitor of tyrosine kinase with IC50 of 6.7 nM, 1.9 nM and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. This compound exhibits antitumor activity.
Ningetinib c-Met inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 556.58

Jump to

Quality Control

Batch: S687001 DMSO]20 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.82%
99.82

Solubility

In vitro
Batch:

DMSO : 20 mg/mL (35.93 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 556.58 Formula

C31H29FN4O5

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1394820-69-9 -- Storage of Stock Solutions

Synonyms CT-053, DE-120, CT053PTSA Smiles CC1=C(C(=O)N(N1C)C2=CC=CC=C2)C(=O)NC3=CC(=C(C=C3)OC4=C5C=CC(=CC5=NC=C4)OCC(C)(C)O)F

Mechanism of Action

Targets/IC50/Ki
Axl
(Cell-free assay)
1.0 nM
VEGFR2
(Cell-free assay)
1.9 nM
c-Met
(Cell-free assay)
6.7 nM
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04992858 Not yet recruiting
Advanced NSCLC
Sunshine Lake Pharma Co. Ltd.
 November 27 2022 Phase 2
NCT03975907 Active not recruiting
Multiple Myeloma
CARsgen Therapeutics Co. Ltd.|Beijing Chao Yang Hospital|The First Affiliated Hospital of Soochow University|Xinhua Hospital Shanghai Jiao Tong University School of Medicine|Tianjin Medical University General Hospital|First Affiliated Hospital of Zhejiang University|Beijing Hospital|Shanghai Tongji Hospital Tongji University School of Medicine|First Affiliated Hospital of Wenzhou Medical University|Xiangya Hospital of Central South University|Peking University People''s Hospital|Qilu Hospital of Shandong University|Sun Yat-sen University|First Affiliated Hospital Sun Yat-Sen University
 June 10 2019 Phase 1|Phase 2
NCT04577703 Completed
Advanced Solid Tumors
Sunshine Lake Pharma Co. Ltd.
 February 8 2014 Phase 1
NCT02022501 Completed
Age-Related Macular Degeneration
Santen Inc.
 January 2014 Phase 1|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map